JP2018513149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513149A5 JP2018513149A5 JP2017552973A JP2017552973A JP2018513149A5 JP 2018513149 A5 JP2018513149 A5 JP 2018513149A5 JP 2017552973 A JP2017552973 A JP 2017552973A JP 2017552973 A JP2017552973 A JP 2017552973A JP 2018513149 A5 JP2018513149 A5 JP 2018513149A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable domain
- chain variable
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 6
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021086783A JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
| JP2022101169A JP2022118222A (ja) | 2015-04-08 | 2022-06-23 | Ｃｄ３８に結合する抗体治療剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144901P | 2015-04-08 | 2015-04-08 | |
| US62/144,901 | 2015-04-08 | ||
| PCT/US2016/026567 WO2016164669A2 (en) | 2015-04-08 | 2016-04-08 | Antibody therapeutics that bind cd38 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086783A Division JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513149A JP2018513149A (ja) | 2018-05-24 |
| JP2018513149A5 true JP2018513149A5 (cg-RX-API-DMAC7.html) | 2019-05-16 |
| JP7068825B2 JP7068825B2 (ja) | 2022-05-17 |
Family
ID=57072959
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552973A Active JP7068825B2 (ja) | 2015-04-08 | 2016-04-08 | Ｃｄ３８に結合する抗体治療剤 |
| JP2021086783A Active JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
| JP2022101169A Pending JP2022118222A (ja) | 2015-04-08 | 2022-06-23 | Ｃｄ３８に結合する抗体治療剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086783A Active JP7273101B2 (ja) | 2015-04-08 | 2021-05-24 | Ｃｄ３８に結合する抗体治療剤 |
| JP2022101169A Pending JP2022118222A (ja) | 2015-04-08 | 2022-06-23 | Ｃｄ３８に結合する抗体治療剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10059774B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3280443B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7068825B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107921122B (cg-RX-API-DMAC7.html) |
| AR (1) | AR104213A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2927119T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201702264A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2016164656A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10100118B2 (en) | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
| EP3280443B1 (en) | 2015-04-08 | 2022-08-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| AU2018275359C1 (en) | 2017-06-02 | 2022-02-03 | Pfizer Inc. | Antibodies specific for FLT3 and their uses |
| AU2018280871B2 (en) | 2017-06-08 | 2024-09-26 | Black Belt Therapeutics Ltd | CD38 modulating antibody |
| CA3066547A1 (en) | 2017-06-08 | 2018-12-13 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| EP3641831B1 (en) | 2017-06-20 | 2024-11-06 | Sorrento Therapeutics, Inc. | Cd38 antibody drug conjugate |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CA3073085A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3072296A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
| CA3080109A1 (en) * | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| WO2019173837A1 (en) * | 2018-03-09 | 2019-09-12 | Sorrento Therapeutics, Inc. | Dimeric antigen receptors (dar) |
| JP7637510B2 (ja) * | 2018-06-20 | 2025-02-28 | ビバソル， インコーポレイテッド | Ｃｄ３８に結合するバリアント抗体 |
| KR20210057752A (ko) * | 2018-09-11 | 2021-05-21 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-cd38 항체, 이의 항원 결합 단편, 및 제약 용도 |
| CN114524877A (zh) * | 2019-03-29 | 2022-05-24 | 索伦托药业有限公司 | 结合cd38的经工程改造的变异抗体 |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| CN114269770B (zh) * | 2019-07-03 | 2025-02-25 | 肽梦想株式会社 | Cd38结合剂及其用途 |
| JP2022544990A (ja) * | 2019-08-19 | 2022-10-24 | パンディオン・オペレーションズ・インコーポレイテッド | Ｐｄ－１アゴニストによる標的化免疫容 |
| CA3160173A1 (en) | 2019-12-05 | 2021-06-10 | Sorrento Therapeutics, Inc. | Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US20230235004A1 (en) * | 2020-02-21 | 2023-07-27 | Pandion Operations, Inc. | Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins |
| WO2022015956A1 (en) | 2020-07-15 | 2022-01-20 | Sorrento Therapeutics, Inc. | Improved process for dna integration using rna-guided endonucleases |
| MX2023002045A (es) * | 2020-08-19 | 2023-05-08 | Pandion Operations Inc | Anticuerpos anti-pd-1 multiparatopicos y usos de los mismos. |
| EP4211476A4 (en) * | 2020-09-10 | 2024-11-13 | CASI Pharmaceuticals, Inc. | BLOOD SCREENING PROCEDURES |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| JP3589665B2 (ja) | 1992-10-23 | 2004-11-17 | イミュネックス・コーポレーション | 可溶性オリゴマー蛋白質の調製法 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| NZ522700A (en) | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
| US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| JP2008504013A (ja) * | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| CN1976950B (zh) * | 2004-02-06 | 2012-08-29 | 莫佛塞斯公司 | 抗cd38人抗体及其用途 |
| NZ586780A (en) * | 2005-03-23 | 2012-02-24 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| KR20150139636A (ko) * | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
| RS59769B1 (sr) | 2010-06-09 | 2020-02-28 | Genmab As | Antitela protiv humanog cd38 |
| KR101912957B1 (ko) * | 2010-09-27 | 2018-10-29 | 모르포시스 아게 | 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉 |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US9120858B2 (en) * | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
| JP2016534090A (ja) * | 2013-07-15 | 2016-11-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ３８アゴニストの医学的使用 |
| EP3280443B1 (en) | 2015-04-08 | 2022-08-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
-
2016
- 2016-04-08 EP EP16777327.4A patent/EP3280443B1/en active Active
- 2016-04-08 ES ES16777327T patent/ES2927119T3/es active Active
- 2016-04-08 CN CN201680033770.3A patent/CN107921122B/zh active Active
- 2016-04-08 JP JP2017552973A patent/JP7068825B2/ja active Active
- 2016-04-08 WO PCT/US2016/026545 patent/WO2016164656A1/en not_active Ceased
- 2016-04-08 TW TW105111134A patent/TW201702264A/zh unknown
- 2016-04-08 EP EP22190744.7A patent/EP4180058A1/en active Pending
- 2016-04-08 CN CN202110836777.1A patent/CN113527495A/zh active Pending
- 2016-04-08 US US15/094,384 patent/US10059774B2/en active Active
- 2016-04-08 US US15/093,773 patent/US9951144B2/en active Active
- 2016-04-08 AR ARP160100954A patent/AR104213A1/es unknown
- 2016-04-08 WO PCT/US2016/026567 patent/WO2016164669A2/en not_active Ceased
-
2018
- 2018-08-04 US US16/055,065 patent/US10800852B2/en active Active
-
2020
- 2020-09-09 US US17/016,104 patent/US11999792B2/en active Active
-
2021
- 2021-05-24 JP JP2021086783A patent/JP7273101B2/ja active Active
-
2022
- 2022-06-23 JP JP2022101169A patent/JP2022118222A/ja active Pending